SLC5A2 and metabolic dysfunction-associated steatotic liver disease: By integrating genetic and experimental evidence, our study suggests that the SGLT2 inhibitor empagliflozin exerts significant benefits in reducing hepatic lipid accumulation, suppressing inflammation, and attenuating fibrosis, thereby supporting its therapeutic potential in NAFLD.